The Allergenic Products Advisory Committee meeting of the FDA has made a positive recommendation of Ragwitek (Short Ragweed Pollen Allergen Extract)...
Merck Inc., announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet...
Merck announced that the FDA has approved Grastek (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy...
ALK Abello announced that the FDA approved Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use for the treatment of short ragweed pollen-induced allergic rhinitis in persons ages five through 65.
ALK announced that Health Canada has approved once-daily Ragwitek (Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) Sublingual Tablet) for the treatment of moderate to severe ragweed pollen allergies in children age five and older.
Objective: Pollen food allergy syndrome (PFAS) is a complex syndrome posing a diagnostic and therapeutic challenge. Our objective was to summarize the available literature regarding its prevalence, pathogenesis, diagnosis, and treatment.
Merck & Co. has announced that the FDA has accepted its biologics license application for MK 3641, a dissolvable tablet...
Stallergenes, announced that the FDA has approved Oralair, the first immunotherapy tablet to be available in the U.S. for the...
The FDA has approved Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use, from Merck, as immunotherapy for the...
Background: Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLIT) may slow this progression.